Gilead Sciences [GILD] vs Merck & Co [MRK] Detailed Stock Comparison
Gilead Sciences
NASDAQ
Loading...
Merck & Co
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Gilead Sciences wins in 4 metrics, Merck & Co wins in 16 metrics, with 0 ties. Merck & Co appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Gilead Sciences | Merck & Co | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 24.06 | 12.31 | Merck & Co |
| Price-to-Book Ratio | 7.44 | 4.16 | Merck & Co |
| Debt-to-Equity Ratio | 130.79 | 71.99 | Merck & Co |
| PEG Ratio | 15.41 | 8.50 | Merck & Co |
| EV/EBITDA | 11.56 | 7.71 | Merck & Co |
| Profit Margin (TTM) | 20.76% | 25.79% | Merck & Co |
| Operating Margin (TTM) | 38.49% | 36.61% | Gilead Sciences |
| EBITDA Margin (TTM) | 38.49% | 36.61% | Gilead Sciences |
| Return on Equity | 32.65% | 36.91% | Merck & Co |
| Return on Assets (TTM) | 12.14% | 14.62% | Merck & Co |
| Free Cash Flow (TTM) | $10.31B | $18.10B | Merck & Co |
| Dividend Yield | 2.84% | 3.01% | Merck & Co |
| 1-Year Return | 49.71% | -30.65% | Gilead Sciences |
| Price-to-Sales Ratio (TTM) | 4.96 | 3.15 | Merck & Co |
| Enterprise Value | $158.60B | $224.78B | Merck & Co |
| EV/Revenue Ratio | 5.52 | 3.53 | Merck & Co |
| Gross Profit Margin (TTM) | 76.90% | 77.98% | Merck & Co |
| Revenue per Share (TTM) | $23 | $25 | Merck & Co |
| Earnings per Share (Diluted) | $4.76 | $6.49 | Merck & Co |
| Beta (Stock Volatility) | 0.35 | 0.39 | Gilead Sciences |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Gilead Sciences vs Merck & Co Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Gilead Sciences | 8.27% | -1.79% | -1.34% | 11.51% | 14.83% | 20.03% |
| Merck & Co | 0.45% | 2.88% | -0.66% | 1.58% | -7.92% | -18.96% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Gilead Sciences | 49.71% | 75.16% | 60.99% | -4.60% | 542.66% | 940.38% |
| Merck & Co | -30.65% | -12.72% | -0.28% | 40.68% | 138.06% | 172.71% |
Performance & Financial Health Analysis: Gilead Sciences vs Merck & Co
| Metric | GILD | MRK |
|---|---|---|
| Market Information | ||
| Market Cap | $142.44B | $200.53B |
| Market Cap Category | Large cap | Mega cap |
| 10 Day Avg. Volume | 5,751,080 | 13,904,610 |
| 90 Day Avg. Volume | 6,288,790 | 15,207,197 |
| Last Close | $119.40 | $80.73 |
| 52 Week Range | $72.43 - $121.38 | $73.31 - $120.30 |
| % from 52W High | -1.63% | -32.89% |
| All-Time High | $123.37 (Jun 22, 2015) | $134.63 (Jun 24, 2024) |
| % from All-Time High | -3.22% | -40.04% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.00% | -0.02% |
| Quarterly Earnings Growth | 0.00% | -0.19% |
| Financial Health | ||
| Profit Margin (TTM) | 0.21% | 0.26% |
| Operating Margin (TTM) | 0.38% | 0.37% |
| Return on Equity (TTM) | 0.33% | 0.37% |
| Debt to Equity (MRQ) | 130.79 | 71.99 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $15.39 | $19.21 |
| Cash per Share (MRQ) | $7.00 | $3.68 |
| Operating Cash Flow (TTM) | $10.37B | $22.75B |
| Levered Free Cash Flow (TTM) | $9.99B | $17.12B |
| Dividends | ||
| Last 12-Month Dividend Yield | 2.84% | 3.01% |
| Last 12-Month Dividend | $3.12 | $2.39 |
Valuation & Enterprise Metrics Analysis: Gilead Sciences vs Merck & Co
| Metric | GILD | MRK |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 24.06 | 12.31 |
| Forward P/E | 15.41 | 8.50 |
| PEG Ratio | 15.41 | 8.50 |
| Price to Sales (TTM) | 4.96 | 3.15 |
| Price to Book (MRQ) | 7.44 | 4.16 |
| Market Capitalization | ||
| Market Capitalization | $142.44B | $200.53B |
| Enterprise Value | $158.60B | $224.78B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 5.52 | 3.53 |
| Enterprise to EBITDA | 11.56 | 7.71 |
| Risk & Other Metrics | ||
| Beta | 0.35 | 0.39 |
| Book Value per Share (MRQ) | $15.39 | $19.21 |
Financial Statements Comparison: Gilead Sciences vs Merck & Co
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | GILD | MRK |
|---|---|---|
| Revenue/Sales | $6.67B | $15.81B |
| Cost of Goods Sold | $1.54B | $3.56B |
| Gross Profit | $5.13B | $12.25B |
| Research & Development | $1.38B | $4.05B |
| Operating Income (EBIT) | $2.49B | $5.55B |
| EBITDA | $3.28B | $6.96B |
| Pre-Tax Income | $1.65B | $5.00B |
| Income Tax | $334.00M | $571.00M |
| Net Income (Profit) | $1.32B | $4.43B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | GILD | MRK |
|---|---|---|
| Cash & Equivalents | $7.93B | $8.63B |
| Total Current Assets | $16.90B | $35.50B |
| Total Current Liabilities | $12.34B | $25.17B |
| Long-Term Debt | $22.15B | $33.48B |
| Total Shareholders Equity | $19.08B | $48.40B |
| Retained Earnings | $10.93B | $66.10B |
| Property, Plant & Equipment | $7.96B | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | GILD | MRK |
|---|---|---|
| Operating Cash Flow | $1.56B | $6.30B |
| Capital Expenditures | $-104.00M | N/A |
| Free Cash Flow | $1.65B | $1.17B |
| Debt Repayment | $-1.76B | $-2.50B |
| Common Stock Repurchase | $-730.00M | $-1.16B |
Short Interest & Institutional Ownership Analysis
| Metric | GILD | MRK |
|---|---|---|
| Shares Short | 22.54M | 28.77M |
| Short Ratio | 2.80 | 1.61 |
| Short % of Float | 0.02% | 0.01% |
| Average Daily Volume (10 Day) | 5,751,080 | 13,904,610 |
| Average Daily Volume (90 Day) | 6,288,790 | 15,207,197 |
| Shares Outstanding | 1.25B | 2.53B |
| Float Shares | 1.24B | 2.51B |
| % Held by Insiders | 0.00% | 0.00% |
| % Held by Institutions | 0.90% | 0.81% |
Dividend Analysis & Yield Comparison: Gilead Sciences vs Merck & Co
| Metric | GILD | MRK |
|---|---|---|
| Last 12-Month Dividend | $3.12 | $2.39 |
| Last 12-Month Dividend Yield | 2.84% | 3.01% |
| 3-Year Avg Annual Dividend | $3.04 | $2.77 |
| 3-Year Avg Dividend Yield | 0.93% | 0.71% |
| 3-Year Total Dividends | $9.12 | $8.31 |
| Ex-Dividend Date | Jun 13, 2025 | Mar 17, 2025 |